skip to Main Content

Dr. Padrón on Biosignatures Found from a Phase 2 Study in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Lacey J. Padrón, PhD, vice president, Informatics, Parker Cancer Institute for Immunotherapy, discusses biosignatures found in a phase 2 study (NCT03214250) in pancreatic cancer. In this open-label, multicenter trial, oncologists examined the efficacy of gemcitabine and nab-paclitaxel plus sotigalimab (Apexigen; formerly APX 005M) and/or nivolumab (Opdivo) in patients with metastatic pancreatic adenocarcinoma.


The study revealed biomarkers of response, particularly to the sotigalimab/chemotherapy and nivolumab/chemotherapy combinations, Padrón explains. Moreover, in the patients’ blood and tumor at baseline, investigators found signals that correlated with longer survival, Padrón adds. Watch here . . .

Back To Top